TLR4 and infection: Based on our results, the vaccine candidate was shown to be highly antigenic and nonallergenic with good stability, solubility, and proper structural conformation, showing appropriate interaction with mouse TLR4 and stimulating adequate levels of humoral and cell-mediated immune responses to confine the infection, although wet laboratory experiments should confirm the actual efficacy of the engineered vaccine model.